Latest Intellectual Property News

Metal Powder Works nearly doubled its powder revenue in Q1 2026 while maintaining strong margins, secured its first NATO defence contract under the UK Ministry of Defence’s Project TAMPA, and advanced its Next Gen powder production system on schedule.

Zinc Mines Ireland (ASX: ZMI) has acquired Dutch metals tech firm Meclex, integrating its proprietary low-temperature hydrometallurgical processes into ZMI’s Kildare zinc project. The move aims to unlock critical mineral value and reduce environmental impact in European zinc and battery recycling markets.

Pure Resources has deepened its partnership with Rice University to develop carbon nanotube fibre thermal management technology aimed at AI and defence markets, leveraging its Garnet Hills graphite for a vertically integrated IP pipeline.

dorsaVi has confirmed that its proprietary RRAM memory technology and neuromorphic IP portfolio work seamlessly together, projecting a tenfold boost in performance for robotics and exoskeleton applications. This breakthrough lays the groundwork for smarter, faster, and more energy-efficient wearable and robotic devices operating at the ultra-edge.

Xenitra Limited has swiftly moved from concept to commercial traction, generating over $100,000 in sales within the first week of launching EZZ Life Sciences products on its blockchain-based OPAL token ecosystem.

Patrys has raised A$3.2 million through a share placement to fund its injectable quetiapine program’s Phase 1A clinical trial and FDA pre-IND preparations.

ION Video Ltd has responded to ASX inquiries by confirming its recent discussions with Meta Platforms and Alphabet remain preliminary, with no binding agreements or commercial terms agreed. The company emphasised that the engagements are exploratory and non-binding, explaining why earlier disclosure was not required.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

ION Video has entered substantive early-stage discussions with Meta and Alphabet, exploring potential applications of its patented video virtualization technology. These talks are part of a broader engagement with major global tech players, though no formal deals have yet been struck.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.